All In Biotech

Drug Trial Radar · NCT07192939

Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis

Last checked: Nov 20, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Oct 29, 2025

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Sponsor type
Industry
First posted
Sep 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of HRS-9813 in subjects with pulmonary fibrosis。

Conditions

  • IPF and PPF

Interventions

  • HRS-9813 capsulesDrug

    HRS-9813 capsule; High dose

  • HRS-9813 capsulesDrug

    HRS-9813 capsule; Low dose

  • HRS-9813 capsule mimeticDrug

    HRS-9813 capsule mimetic

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FVC as a percentage of the predicted valueTime frame: The baseline period lasted until 26weeks after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences & Peking Union Medical College

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.